Condition: Interstitial Lung Disease · Systemic Autoimmune Disease · Rheumatic Diseases · Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs. The purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.
This description comes directly from the study's public registry record.
Deborah Assayag, MD, MAS · 514-934-1934 · deborah.assayag@mcgill.ca
Victoria Nam-Amnath, RN, BScN · 514-934-1934 · victoria.nam-amnath@muhc.mcgill.ca
Always discuss trial participation with your own doctor first.
| RI-MUHC | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05007340